Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial

Anti-diabetic effects of GLP1 analogs are mediated by thermogenic interleukin-6 signaling in adipocytes

“…To investigate the systemic effects of GLP1 analogs, we analyzed the plasma of obese prediabetic patients enrolled in a prospective randomized crossover placebo-controlled double-blinded trial ( NCT02104739 ) ( Figure S1 A) reported previously. 26 Participants were predominantly obese prediabetic males and females ( Table S1 ). Acute changes in postprandial inflammatory and metabolic plasma markers were analyzed 2 h after exenatide or placebo administration.…”

“…# 711-166-152 Biological samples Patient blood samples Hamidi et al. 26 N/A Chemicals, peptides, and recombinant proteins Rodent 58 kcal% (fat) diet Research Diets Cat. # D12331 Liraglutide AdipoGen Life Sciences Cat.…”

“…The design of the prospective randomized crossover placebo-controlled double-blinded trial was reported previously. 26 Eligible subjects were men and women, ages 30 to 70 years, with prediabetes. Prediabetes was defined as impaired fasting glucose (100–125 mg/dL), impaired glucose tolerance (2-h postprandial glucose of 140–199 mg/dL after 75 g oral glucose challenge), and/or a hemoglobin A1C ranging from 5.7% to 6.4%.…”

“…Results from the prospective randomized crossover placebo-controlled double-blinded trial https://clinicaltrials.gov/ct2/show/NCT02104739 have been reported. 26 …”

Skeletal Muscle Microvascular Dysfunction in Obesity-Related Insulin Resistance: Pathophysiological Mechanisms and Therapeutic Perspectives

“…Three-month therapy with the GLP-1 receptor agonist exenatide showed a similar effect to metformin on microvascular endothelial function, inflammatory phenotype, and redox homeostasis, as assessed by reactive hyperaemic index, C-reactive protein (CRP), circulating oxidized low-density lipoprotein, and VCAM-1 [172]. However, in obese patients with insulin resistance, acute treatment with exenatide following a high-fat meal was associated with blunted postprandial vasodilatory response [173]. On the other hand, SGLT2 inhibitors such as empagliflozin, canagliflozin, and dapagliflozin, which are clinically remarkable for their favourable cardiovascular and renal profile in diabetic patients [174], have additionally been suggested to have benefits in obesity.…”